Brokerages Set IDEXX Laboratories, Inc. (NASDAQ:IDXX) PT at $751.00

IDEXX Laboratories, Inc. (NASDAQ:IDXX) has received a consensus rating of “Moderate Buy” from the eleven ratings firms that are currently covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $751.00.

Several brokerages recently issued reports on IDXX. UBS Group cut their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Piper Sandler cut their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. Citigroup began coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target for the company. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Stifel Nicolaus cut their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st.

Institutional Investors Weigh In On IDEXX Laboratories

Several institutional investors and hedge funds have recently added to or reduced their stakes in IDXX. SHP Wealth Management bought a new stake in IDEXX Laboratories during the fourth quarter worth $26,000. Virtus Advisers LLC bought a new stake in IDEXX Laboratories during the third quarter worth $26,000. Park Place Capital Corp bought a new stake in IDEXX Laboratories during the fourth quarter worth $29,000. WealthCollab LLC bought a new stake in IDEXX Laboratories during the second quarter worth $30,000. Finally, Greykasell Wealth Strategies Inc. bought a new stake in IDEXX Laboratories during the third quarter worth $35,000. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Trading Up 0.7%

Shares of IDXX stock opened at $564.74 on Tuesday. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The stock has a market cap of $44.55 billion, a P/E ratio of 41.59, a price-to-earnings-growth ratio of 3.07 and a beta of 1.55. The stock has a 50 day simple moving average of $563.32 and a 200 day simple moving average of $632.63. IDEXX Laboratories has a 1 year low of $506.91 and a 1 year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period in the previous year, the company posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, research analysts predict that IDEXX Laboratories will post 14.68 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.